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ABSTRACT
Prostate and breast cancers frequently metastasize to bone. The physiological 
bone homeostasis is perturbed once cancer cells proliferate at the bone metastatic 
site. Tumors are complex structures consisting of cancer cells and numerous stroma 
cells.
In this study, we show that osteolytic cancer cells (PC-3 and MDA-MB231) induce 
transcriptome changes in the bone/bone marrow microenvironment (stroma). This 
stroma transcriptome differs from the previously reported stroma transcriptome 
of osteoinductive cancer cells (VCaP). While the biological process “angiogenesis/
vasculogenesis” is enriched in both transcriptomes, the “vascular/axon guidance” 
process is a unique process that characterizes the osteolytic stroma. In osteolytic 
bone metastasis, angiogenesis is denoted by vessel morphology and marker 
expression specific for arteries/arterioles. Interestingly, intra-tumoral neurite-
like structures were in proximity to arteries. Additionally, we found that increased 
numbers of mesenchymal stem cells and vascular smooth muscle cells, expressing 
osteolytic cytokines and inhibitors of bone formation, contribute to the osteolytic 
bone phenotype.
Osteoinductive and osteolytic cancer cells induce different types of vessels, 
representing functionally different hematopoietic stem cell niches. This finding 
suggests different growth requirements of osteolytic and osteoinductive cancer cells 
and the need for a differential anti-angiogenic strategy to inhibit tumor growth in 
osteolytic and osteoblastic bone metastasis.
INTRODUCTION
Prostate and breast cancers are frequently 
diagnosed solid cancers that often metastasize to bone 
[1, 2]. Bone metastases are diagnosed in approximately 
70% of advanced prostate and breast cancer patients 
[3]. Proliferation of cancer cells at the bone metastatic 
site causes a number of skeletal-related events, such as 
severe pain, fractures, spinal cord/intervertebral nerve 
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compression and hypercalcemia. Even today, bone 
metastases remain incurable and therapies are limited to 
prevent skeletal-related events and to control pain.
Nowadays, it is widely accepted that the tumor-
associated microenvironment supports cancer cell growth 
at the primary and metastatic site. Once disseminated 
cancer cells proliferate at the bone metastatic site, 
normal bone physiology, characterized by balanced bone 
formation and resorption, is perturbed. Cancer cells either 
stimulate an excess of bone formation (osteoblastic or 
osteosclerotic bone metastasis) or stimulate an excess 
of bone resorption with concomitant block of bone 
formation (osteolytic bone metastasis) [4]. Prostate cancer 
cells preferentially induce osteoblastic bone metastasis, 
whereas breast cancer cells predominantly display an 
osteolytic bone phenotype. These two distinct stroma 
responses suggest that cancer cells have different growth 
requirements.
Osteolytic cancer cell-derived factors, such as 
parathyroid hormone like hormone (PTHLH/PTHrP), 
interleukin (IL)1, IL6, IL8, IL10, receptor activator 
of nuclear factor kappa B ligand (RANKL), colony 
stimulating factor 1 (CSF1), tumor necrosis factor α 
(TNFα) and Jagged1, directly or indirectly stimulate 
osteoclastogenesis [5, 6]. Additionally, osteolytic prostate 
cancer cells secrete the bone morphogenetic protein 
(BMP) antagonist, noggin, which blocks bone formation, 
contributing to the progression of the osteolytic lesion [7].
Few studies addressed the stromal changes occurring 
in osteolytic bone metastasis. According to the “vicious 
cycle” hypothesis the major relevant biological processes 
are increased osteoclastogenesis and activated osteoclastic 
bone resorption. Bone resorption releases bone matrix 
embedded growth factors, such as transforming growth 
factor beta (TGFβ), insulin-like growth factor 1 (IGF1) 
and calcium ions, which further fuel cancer cell growth 
and secretion of PTHLH, thus amplifying and perpetuating 
the process [4, 8]. Other studies highlighted that stroma 
cell derived factors are fundamental to release soluble 
RANKL and Tgfβ from their latent forms [9–11]. One of 
the early events, both in primary tumors and the metastatic 
site, is the stimulation of angiogenesis by cancer cell-
derived factors [12]. However, the role of angiogenesis 
in bone metastasis in general [13, 14] and specifically in 
osteolytic bone metastasis [15] is almost unexplored.
In the clinics the strategy to inhibit bone metastatic 
tumor growth is based on the vicious cycle hypothesis 
and therefore, inhibition of bone resorption remains the 
treatment of choice. In the clinical setting bisphosphonate 
(BP)-mediated inhibition of bone resorption is an effective 
strategy to reduce skeletal-related events [16], despite 
the lack of proof for a direct negative impact of BPs on 
cancer cell growth and tumor mass. In animal models of 
bone metastasis, BP treatment effectively abolishes bone 
resorption, however, with no effect on total tumor burden 
as cancer cell proliferation persists [17, 18]. This suggests 
that mechanisms other than bone resorption support cancer 
cell growth at the bone metastatic site. Our current study 
is designed to systematically analyze osteolytic cancer 
cell induced molecular changes in the bone/bone marrow 
stroma.
RESULTS
Osteolytic prostate and breast cancer cells alter 
the bone/bone marrow stroma transcriptome
We took advantage of bone metastasis xenograft 
models to identify the molecular changes in the bone/
bone marrow stroma in response to osteolytic cancer 
cells. In this study, osteolytic human prostate (PC-3) or 
breast (MDA-MB231) cancer cells were intra-osseously 
inoculated into the bone marrow cavity of tibial bones 
of immunocompromised mice. Figure 1A outlines the 
experimental strategy to define the molecular changes in 
the stroma of osteolytic bone metastasis. RNA sequencing 
data were explored by using a principal component 
analysis (PCA). The PCA plot showed a distinct separation 
of control bone samples from the cancer cell-xenografted 
samples, showing that osteolytic cancer cells alter the 
bone/bone marrow stroma transcriptome (Figure 1B). 
Interestingly, prostate and breast cancer cell-xenografted 
bone samples also separated from each other in the PCA 
plot. This observation shows that despite the capacity of 
osteolytic prostate and breast cancer cell in inducing an 
osteolytic bone phenotype, the regulation of genes is not 
identical. When compared to control bones, 2141 and 6676 
stroma genes were differentially expressed in PC-3 and 
MDA-MB231 xenografts, respectively (Supplementary 
Tables 1 and 2). In total, 810 stroma genes were 
differentially expressed in both, PC-3 and MDA-MB231 
xenografts (fold change > ±2, adjusted p value < 0.01) 
(Figure 1C, Supplementary Table 3). The VENN diagram 
illustrates that the osteolytic stroma response consists 
of two components, (1) a shared response component 
independent of cancer cell origin and (2) a specific 
response component depending on cancer cell origin. The 
majority of differentially expressed stromal genes were 
up- or down-regulated consistently in both xenografts, 
which was illustrated by the scatter plot displaying the 
log2 fold change in PC-3 versus MDA-MB231 xenografts 
(Figure 1D). Subsequently, our analysis is focused on 
overlapping differentially expressed genes showing a 
concordant gene regulation in both xenograft models. It 
is likely that those are important genes determining the 
osteolytic phenotype. The bar graphs in Figure 1E-1G 
display the top 50 annotated, up-regulated stroma genes 
and their fold change in PC-3 xenografts (Figure 1E), 
MDA-MB231 xenografts (Figure 1F) and genes common 
to both, PC-3 and MDA-MB231 xenografts (Figure 1G).
Taken together, these findings indicate that 
osteolytic cancer cells of different origin elicit a bone/bone 
marrow stroma response consisting of a (1) shared and (2) 
specific component.
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Figure 1: Bones xenografted with osteolytic prostate and breast cancer cells alter the gene expression profile of the 
bone/bone marrow stroma. (A) Flow chart outlining experimental (blue) and bioinformatic (grey) steps used to define the stroma 
response signature in osteolytic bone metastasis (OL-BMST) (orange). (B) Principle component analysis showing the sample distribution 
of prostate (blue - PC-3 cell line) and breast (red - MDA-MB231 cell line) cancer cell line xenografted bones, Ep156T xenografted bones 
(grey) and intact bones (black). Each dot represents one mouse. (C) Venn diagram showing the number of overlapping and unique genes 
differentially expressed in PC-3 (p value < 0.01) and MDA-MB231 (p value < 0.01) xenografted bones versus controls. The sum of 
differentially expressed genes is referred to as the OL-BMST. (D) Scatter plot showing log2 fold change of differentially expressed genes 
in PC-3 and MDA-MB231 xenografts. (E) Top 50 annotated up-regulated genes in the PC-3 xenografts. (F) Top 50 annotated up-regulated 
genes in the MDA-MB231 xenografts. (G) Top 50 annotated up-regulated genes common to both, PC-3 and MDA-MB231 xenografts.
Oncotarget28880www.oncotarget.com
In the bone/bone marrow stroma osteolytic 
cancer cells induce pathways linked to 
angiogenesis and axon guidance
We analyzed pathways, biological processes (gene 
ontology (GO) terms), protein interactions and upstream 
regulators represented in the transcriptome to identify 
changes occurring in the bone/bone marrow stroma in 
response to osteolytic cancer cells.
ECM-receptor interaction, axon guidance, focal 
adhesion, hedgehog/Tgfβ/Wnt signaling pathways and 
cardiomyopathy were significantly enriched pathways (p 
value ≤ 0.05) in the up-regulated stroma genes common 
to PC-3 and MDA-MB231 xenografts (Figure 2A). The 
down-regulated stroma genes were significantly enriched 
for pathways (p value ≤ 0.05) associated to homologous 
recombination, cell cycle, hematopoietic cell lineage, 
spliceosome metabolism and purine metabolism (Figure 
2A). Prominent significantly enriched biological processes 
were collagen metabolic process, ECM organization, 
blood vessel development, bone development and axon 
development (FDR ≤ 0.001) (Figure 2B). Accordingly, 
the protein network analysis of the osteolytic stroma 
transcriptome revealed collagens (Col3a1, Cold5a1, 
Col6a2), matrix metalloprotease 2 (Mmp2) and Elastin as 
the central protein nodes with most interaction partners 
(Figure 2C). We performed an upstream molecule 
analysis to predict molecules inducing the stroma 
response in osteolytic bone metastasis. Thirty-seven 
shared activated upstream regulators were identified for 
the PC-3 and MDA-MB231 xenografts (Table 1). The 
upstream regulators consist of 8 growth factors (Bmp2/4, 
Ctgf, Gdf2, Igf1, Pdgfb, Tgfβ1/3), 4 cytokines (Il1a, 
Il13, Tnfsf11, Wnt3a), transcription regulators (Cdkn2a, 
Ctnnb1, Htt, Jun, Keap1, Nupr1, Rb1, Smad3, Smarca4, 
Smarcb1, Tp53, Twist1) and one miRNA (let-7) and kinase 
(Map2k1). Tgfβ1 had the highest activation score (4.8 and 
8.8 in PC-3 and MDA-MB231 xenografts, respectively) 
and stringency (2.3E-17 and 6.2E-69 in PC-3 and MDA-
MB231 xenografts, respectively).
Taken together, osteolytic and osteoinductive 
cancer cells both induce angiogenesis in the bone/bone 
marrow stroma. However, only osteolytic cancer cells 
concomitantly induce axon guidance.
Genes of the axon guidance pathway are 
specifically induced in the stroma of osteolytic 
bone metastasis
The axon guidance pathway was one of the most 
significantly enriched pathways in the stroma of osteolytic 
bone metastasis. To validate the differential gene expression 
of axon guidance pathway family members, we measured 
their expression in the stroma of osteolytic bone metastasis 
using mouse-specific real time PCR primers (Figure 3A, 
3B). Additionally, we investigated the same gene panel in 
the stroma of osteoblastic bone metastasis (Figure 3C) to 
determine whether these genes are specific to the osteolytic 
stroma response. The genes of the axon guidance pathways 
were either grouped to ephrin (ephrin ligands, ephrin 
receptors, ephrin signaling), semaphorin (semaphorin 
ligands, semaphorin receptors) or slit (slit ligands, slit 
receptor) family members. Genes that could not be assigned 
to any of these category were grouped to the panel “others”.
Out of the 49 measured genes, the following genes 
were significantly induced in the stroma of one or both 
models of osteolytic bone metastasis, but not in the 
stroma of osteoblastic bone metastasis: ephrin ligands 
(Efna5, Efnb2) ephrin receptors (Epha3, Epha4, Ephb1, 
Ephb2, Ephb4) ephrin signaling molecules (Ngef, Rsg3), 
semaphorin ligands (Sema3b, Sema3c, Sema3f, Sema6c, 
Sema7a), semaphorin receptors (Ntn4, Met, Itgb1, Rnd1), 
slit ligands (Slit2, Slit3) and one gene (Rasa1) out of 
the category “others”. Two significantly induced genes, 
Nfat5 and Cdc42, were uniquely induced in the stroma of 
osteoblastic bone metastasis, however, not in the stroma of 
osteolytic bone metastasis.
These findings suggest that the gene regulation of 
numerous members of the axon guidance pathway can be 
specifically attributed to the osteolytic stroma response.
Markers associated with arteries are 
significantly upregulated in the stroma of 
osteolytic bone metastasis
The comparison of the biological processes of the 
osteolytic stroma response with the previously published 
biological processes in the osteoblastic bone metastasis-
associated stroma (OB-BMST)[19], showed that most 
biological processes were shared. Processes related to 
angiogenesis, ECM remodeling, cell adhesion and skeletal 
system development were enriched in both osteolytic and 
osteoblastic stroma transcriptomes.
In the RNA sequencing data genes linked to arteries 
(Elastin, Lamb1, Acta2), pericytes (Cspg4/Ng2, Pdgfrb, 
Sca1 (Ly6a)) and neurons/neurites (Gap43, Tubb3) were 
up-regulated in the stroma of osteolytic bone metastasis, 
(Figure 4A). First, we validated the differential gene 
expression of these markers in the stroma of osteolytic 
and osteoblastic bone metastasis using mouse-specific real 
time PCR primers (Figure 4B-4J). Endomucin mRNA was 
up-regulated in both, osteolytic and osteoblastic, stroma 
transcriptomes; however, the extent of induction was higher 
in osteoblastic bone metastasis as compared to osteolytic 
bone metastasis (Figure 4B). The artery markers, Acta2 
and Elastin, were significantly up-regulated in response 
to osteolytic cancer cells, however, not in response to 
osteoinductive cancer cells (Figure 4C and 4D). Lamb1, 
another artery marker, was significantly up-regulated in 
both, osteolytic and osteoblastic, stroma transcriptomes 
(Figure 4E). Cspg4/Ng2 and Pdgfrb were significantly up-
regulated in the stroma of both osteolytic and osteoblastic 
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bone metastasis and also the induction level was not 
significantly different (Figure 4F and 4G). Sca1 (Ly6a) was 
only significantly up-regulated in MDA-MB231 xenografts, 
however, not in PC-3 xenografts and VCaP-xenografts 
(Figure 4H). In the literature, it has been reported that the 
vascular and neuronal networks are tightly linked, which 
Figure 2: KEGG pathways, GO terms and protein interaction network of the osteolytic stroma response. (A) Enriched 
pathways common to both, PC-3 and MDA-MB231 xenografts. (B) Enriched biological processes common to both, PC-3 and MDA-
MB231 xenografts. (C) Protein interaction network generated from differentially expressed genes common to both, PC-3 and MDA-
MB231 xenografts. The line thickness positively correlates with the confidence score that was obtained for each protein interaction.
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Table 1: Activated upstream regulators common to PC-3 and MDA-MB231 xenografts
  PC-3 xenografts MDA-MB231 xenografts
Upstream Regulator Molecule Type Activation z-score
p-value of 
overlap
Activation 
z-score
p-value of 
overlap
TGFB1 growth factor 4.8 2.31E-17 8.8 6.24E-69
TP53 transcription regulator 3.8 5.13E-13 4.8 4.40E-47
ERBB2 kinase 2.5 1.56E-10 3.2 4.55E-29
BNIP3L other 4.4 4.04E-08 3.3 2.43E-13
TWIST1 transcription regulator 2.2 9.07E-08 3.6 1.19E-10
thioacetamide chemical toxicant 3.2 9.69E-07 2.5 1.15E-16
camptothecin chemical reagent 3.5 1.27E-06 3.4 2.38E-17
WNT3A cytokine 2.9 3.90E-06 4.3 3.08E-08
NUPR1 transcription regulator 5.1 8.03E-06 3.2 2.44E-10
CTNNB1 transcription regulator 2.8 1.10E-05 3.8 2.75E-22
SPARC other 2.4 1.14E-05 2.7 8.81E-09
bleomycin chemical drug 3.0 1.88E-05 4.5 8.35E-18
GDF2 growth factor 2.5 1.91E-05 3.3 7.59E-08
BMP2 growth factor 3.1 2.46E-05 3.4 1.63E-04
HTT transcription regulator 2.4 3.09E-05 2.3 6.26E-15
SMAD3 transcription regulator 3.3 3.24E-05 4.4 2.96E-15
SMARCA4 transcription regulator 2.2 3.79E-05 2.9 6.92E-14
Tgf beta group 3.4 5.14E-05 5.4 1.11E-19
CDKN2A transcription regulator 3.7 7.18E-05 5.0 1.37E-18
RB1 transcription regulator 2.9 7.61E-04 2.7 2.38E-10
CTGF growth factor 2.8 1.22E-03 2.6 1.19E-04
RETNLB other 2.9 1.48E-03 3.5 1.14E-11
TGFB3 growth factor 2.8 1.97E-03 5.2 7.68E-09
SMARCB1 transcription regulator 2.3 2.22E-03 3.0 4.39E-12
IL13 cytokine 2.0 2.30E-03 2.4 3.11E-13
Cg complex 2.2 2.88E-03 6.3 1.33E-19
Am 580 chemical toxicant 2.2 3.82E-03 2.2 6.18E-03
tretinoin chemical - endogenous mammalian 3.7 7.93E-03 4.3 1.15E-36
TNFSF11 cytokine 2.5 7.94E-03 3.3 4.94E-20
let-7 microrna 2.1 7.96E-03 2.6 8.69E-17
JUN transcription regulator 2.2 1.08E-02 2.9 2.64E-16
KEAP1 transcription regulator 2.4 1.45E-02 2.1 4.45E-03
ochratoxin A chemical toxicant 2.2 1.45E-02 3.4 4.45E-03
(Continued )
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is also confirmed by our pathway analysis. In our RNA 
sequencing data, we found that the neurite/neuronal marker, 
Gap43 and β3 tubulin, were significantly up-regulated in 
the stroma of osteolytic bone metastasis (Figure 4A). Only 
the up-regulation of Gap43 was confirmed using mouse-
specific real time PCR probes (Figure 4I).
Taken together, these findings suggest that markers 
associated with arteries are specifically up-regulated in the 
stroma of osteolytic bone metastasis.
The stroma of osteolytic bone metastasis is 
comprised of an arterial network
To characterize the vessels present in osteolytic and 
osteoblastic bone metastases, we analyzed the protein 
expression of endothelial cells markers (endomucin and 
Cd105), artery markers (αSMA and Elastin), pericyte 
markers (Cspg4/Ng2, Pdgfrb, Sca1) and neurite/neuronal 
marker (Gap43 and β3 tubulin) (Figure 5).
Endomucin immunoreactivity was found in the 
normal bone marrow and in the stroma of osteolytic and 
osteoblastic bone metastasis (Figure 5A). In the stroma of 
osteolytic bone metastasis, endomucin positive cells were 
detected as elongated, intra-tumoral vessel-like structures, 
whereas in the osteoblastic bone metastasis endomucin-
labeled structures were similar to the sinusoidal vessel 
morphology of the control bone marrow. Interestingly, in 
VCaP tumors, endomucin-positive cells surround tumor 
areas and associated to the bone-forming surfaces, whereas 
the intra-tumoral regions were devoid of endomucin 
immunoreactivity. Cd105 immunoreactivity showed a 
similar expression patterns as endomucin (Figure 5B).
Alpha SMA protein expression in normal bone 
marrow marked arteries/arterioles. Interestingly, the stroma 
of osteoblastic bone metastasis was devoid of αSMA 
immunoreactivity (Figure 5C). In the stroma of osteolytic 
bone metastasis αSMA positive cells were distributed 
in vessel-like structures throughout the entire stroma. 
When we stained for an epithelial marker (marking cancer 
cells) and αSMA in PC-3 and MDA-MB231 xenografts 
in consecutive sections, αSMA positive cells did not 
express the epithelial marker, Epcam and Pan-cytokeratin, 
respectively (Supplementary Figure 1). To confirm that 
αSMA positive cells were of stromal origin and not cancer 
cells expressing a mesenchymal marker, we performed 
laser-captured micro-dissection of αSMA positive cells 
from MDA-MB231 xenografts. In RNA samples of αSMA 
positive cells only mouse Acta2 was detected, whereas 
human Acta2 was absent (data not shown). This analysis 
substantiates the stroma origin of αSMA positive cells. We 
used a model of systemic bone metastasis, in which we 
injected MDA-MB231 cells into the left ventricle of the 
heart and analyzed the protein expression of αSMA in bone 
metastasis specimens. The accumulation of αSMA positive 
cells was observed in the same way as in the intra-osseous 
inoculated xenograft model (Supplementary Figure 2A). 
Furthermore, we demonstrated that αSMA positive cells 
also accumulated in immune-competent animals (syngeneic 
mouse model, in which 4T1.2 cells were injected intra-
osseous) (Supplementary Figure 2B).
To further characterize the marker expression of 
the intra-tumoral vessels, animals bearing intra-osseous 
xenografts of PC-3, MDA-MB231 and VCaP cancer cells 
and sham-operated animals were intra-venously injected 
with Alexa Fluor 633, a dye that specifically labels arteries 
by binding to elastin [20]. In control bone marrow, the 
central artery and arterioles were labeled with Alexa Fluor 
633, whereas in PC-3 and MDA-MB231 xenografts, 
intra-tumoral vessel-like structures were Alexa Fluor 633 
labeled (Figure 5D). In contrast, osteoinductive VCaP 
xenografts were devoid of any Alexa Fluor 633 staining 
after in vivo labeling.
The protein expression analysis of pericyte markers, 
namely Cspg4 (Ng2), Pdgfrb and Ly6a (Sca1), showed that 
Cspg4 (Ng2) and Ly6a (Sca1) positive cells are associated 
to arteries/arterioles in normal bone marrow. Pdgfrb 
marked pericytes and also scattered cells in the normal 
bone marrow. There are numerous Cspg4 (Ng2) positive 
cells found intra-tumoral in osteolytic bone metastasis. 
In VCaP xenografts few Cspg4 (Ng2) positive cells were 
found around the tumor but not within the tumor. A similar 
expression pattern was found for Ly6a (Sca1) positive 
cells. In osteolytic bone metastasis Pdgfrb positive, stripe-
like structures were found in the tumor, whereas in VCaP 
  PC-3 xenografts MDA-MB231 xenografts
Upstream Regulator Molecule Type Activation z-score
p-value of 
overlap
Activation 
z-score
p-value of 
overlap
IL1A cytokine 2.6 1.52E-02 5.5 6.60E-10
PDGFB growth factor 2.4 2.32E-02 3.0 2.95E-05
MAP2K1 kinase 2.0 2.90E-02 2.7 2.02E-07
ERK group 2.7 4.48E-02 4.3 2.16E-16
The table lists upstream regulators with their corresponding molecule type, activation z-score and p-value for both, PC-3 
and MDA-MB231 xenografts.
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xenografts only few Pdgfrb positive cells were found in 
proximity to the bone surface (Figure 5E-5G).
In normal bone marrow β3 tubulin immunoreactivity 
is detected in cells close to the central artery. In contrast, 
in the stroma of osteolytic bone metastasis, β3 tubulin 
positive cells were scattered throughout the stroma. A 
higher frequency of β3 tubulin positive cells with different 
morphology (elongated, stripe-like) was seen in MDA-
MB231 xenografts as compared to PC-3 xenografts. 
The immunoreactivity in PC-3 xenografts was less 
Figure 3: A subset of axon guidance molecules is exclusively induced in osteolytic bone metastasis. Fold change expression 
levels of axon guidance genes in osteolytic (PC-3 and MDA-MB231 xenografts) and osteoblastic (VCaP xenografts) bone metastasis 
compared to sham-operated animals. Expression levels of ephrin family members (blue bars), semaphorin family members (green bars), 
Slit family members (grey bars) and others (white bars) in (A) PC-3, (B) MDA-MB231 and (C) VCaP xenografts. Values are shown as fold 
change (mean ± SD) relative to sham-operated animals. *, P < 0.01; **, P < 0.001; ***, P < 0.0001; ****, P < 0.0001.
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Figure 4: Expression analysis of endothelial cell, artery, pericyte and neuronal/neurite markers in osteolytic and 
osteoblastic bone metastasis. (A) Fold change of genes, associated to endothelial cells, arteries, pericytes and neurons/neurites, 
measured by RNA sequencing (for PC-3 and MDA-MB231 xenografts versus controls) or microarray data (for VCaP xenografts versus 
controls). B-J. Relative expression levels of endothelial cell (B), artery (C-E), pericyte (F-H) and neuron/neurite (I and J) markers in 
osteolytic (PC-3 and MDA-MB231 xenografts) and osteoblastic (VCaP xenografts) bone metastasis and corresponding sham-operated 
animals. Expression levels are shown for PC-3 (blue bar), MDA-MB231 (red bar), VCaP (black bar) xenografts and corresponding sham-
operated animals (white bar: sham-operated animals of PC3 and MDA-MB231 xenografts models; grey bar: sham-operated animals of 
VCaP xenografts). Values for each gene is shown as relative expression to mouse B2M (mean ± SD). *, P < 0.01; **, P < 0.001; ***, P < 
0.0001; ****, P < 0.0001, ns - not significant.
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pronounced. The stroma of VCaP xenografts showed rare 
β3 tubulin positive cells (Figure 5H).
Additionally, we analyzed the protein expression of the 
early neurite marker Gap43. Gap43 expression was detected 
in cells close to the central artery and arterioles in normal 
bone marrow. Gap43 protein expression was found only 
in osteolytic bone metastasis but not in osteoblastic bone 
metastasis (Figure 5I). Gap43 expression was detected in 
close proximity to Alexa Fluor 633 labeled cells (Figure 5J).
In summary, osteolytic cancer cells induce an 
accumulation of cells staining positive for αSMA, Elastin, 
Pdgfrb and Ly6a (Sca1) (Figure 5K).
Osteolytic cytokines and BMP/Wnt antagonists 
are expressed by mesenchymal stem cells and 
αSMA positive cells
Osteolytic bone metastases are characterized by 
increased bone resorption and decreased bone formation. 
Previously, we reported that prostate cancer cells secrete 
the BMP antagonist, noggin, and, thereby, bone formation 
is inhibited [7]. Interestingly, our RNA sequencing data 
pinpointed that the stroma serves as an additional source of 
BMP (Chordin, Noggin, Sclerostin) and Wnt antagonists 
(Dkk1, Dkk2, Dkk3, Frzb) (see supplementary results).
The osteolytic bone metastasis stroma contained 
an accumulation of αSMA positive cells and increased 
numbers of mesenchymal stem cells (MSCs) (see 
supplementary results).
To identify whether these two cell types express 
genes encoding osteolytic cytokines (Rankl and Csf1) and/
or BMP/Wnt antagonists (Dkk1-3, Sost, Chordin, Noggin, 
Frzb), we analyzed mRNA expression of FACS-sorted 
MSCs and αSMA positive cells isolated from MDA-
MB231 intra-osseous xenografts and control bones.
Alpha SMA positive cells isolated from the bone/
bone marrow of control animal express Noggin, which 
was also expressed by αSMA positive cells isolated from 
MDA-MB231 xenografts. Interestingly, αSMA positive 
Figure 5: The stroma of osteolytic bone metastasis is comprised of an arterial network. Immunohistochemical or 
immunofluorescent detection of endothelial cell markers (Endomucin (A) and Cd105 (Endoglin) (B)), artery markers (αSMA (C) and 
Elastin (D)), pericyte markers (Cspg4/Ng2 (E), Pdgfrb (F) and Sca1 (G)) and neuronal/neurite markers (β3 tubulin (H) and Gap43 (I) in 
control bones, MDA-MB231 xenografts, PC-3 xenografts and VCaP xenografts. (J) Immunofluorescent detection of Gap43 positive cells 
in proximity to Elastin positive cells in PC-3 and MDA-MB231 xenografts. Scale bar = 50 μm. (K) Quantification of percent positive 
staining area per field of view (FOV) for endomucin, Cd105 (Endoglin), αSMA, Alexa Fluor 633 (=Elastin), Cspg4/Ng2, Pdgfrb, Sca1, β3 
tubulin and Gap43.
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cells from tumors additionally expressed Rankl, Csf1, 
Dkk2 and Dkk3 (Figure 6A and 6B).
MSCs from sham-operated animals expressed Csf1, 
Dkk2 and Dkk3. The expression pattern in MSCs isolated 
from MDA-MB231 xenografts was mostly retained, 
however, MSCs additionally expressed Rankl and Frzb 
(Figure 6C and 6D). Noteworthy was also the high 
expression level of Rankl in MSCs isolated from MDA-
MB231 xenografts compared to αSMA positive cells.
In osteolytic bone metastasis, the source of 
osteolytic cytokines can be attributed to MSCs and αSMA 
positive cells. However, the major source of Rankl in 
osteolytic tumors are MSCs. Interestingly, the major 
source of BMP/Wnt antagonists are αSMA positive cells.
Alpha SMA positive cells express genes involved 
in bone turn-over, cell adhesion, neurogenesis 
and Wnt signaling
Alpha SMA positive cells were the predominant 
cell type in the stroma of osteolytic bone metastasis. We 
analyzed which differentially expressed stromal genes 
in osteolytic bone metastasis can be attributed to αSMA 
positive cells. We utilized a published mRNA expression 
dataset (GSE15062), in which smooth muscle cells 
isolated from aortae of 8- to 12-week-old C57BL/6 mice 
were profiled [21]. We compared up-regulated genes in 
PC-3, MDA-MB231, VCaP xenografts and the dataset 
of αSMA positive cells. We focused on genes shared 
between the stroma response of osteolytic bone metastasis 
and the dataset characterizing αSMA positive cells and 
not overlapping with VCaP xenografts. Interestingly, we 
identified 80 genes (Table 2), among which various genes 
are involved in bone turnover (Pkdcc, Tcta, Wisp2), cell 
adhesion (Ddr1, Itga3, Itgbl1, Scarf2, Wtip), neurogenesis 
(Chac1, Crlf1, Dbn1, Ncs1, Nrep, Serpinf1, Thy1, Unc5b) 
and Wnt signaling (Dact3, Dkk3, Frzb, Fzd2, Trabd2b).
The growth support of αSMA positive cells 
towards cancer cells might be diverse, suppression of 
bone formation, on one hand, direct secretion of growth 
factors (Efemp2) on the other hand. In future it would be 
interesting to study the depletion of αSMA positive cells 
Figure 6: Osteolytic cytokine and Wnt/BMP antagonist expression in αSMA positive cells and mesenchymal stem cells 
(MSCs) isolated from control bones and MDA-MB231 xenografts. Relative expression levels of osteolytic cytokines (Rankl, 
Csf1) and Wnt/BMP antagonists (Dkk1, Dkk2, Dkk3, Sost, Chordin, Noggin, Frzb) in αSMA positive cells (A and B) and mesenchymal stem 
cells (MSCs) (C and D) isolated from control bones (A and C) and MDA-MB231 xenografts (B and D).
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in osteolytic bone metastasis and whether this would alter 
growth of osteolytic cancer cells.
Human bone metastasis are characterized by 
distinct vessel morphology
To translate our finding to human bone metastatic 
disease, we next investigated the protein expression of 
αSMA and β3 tubulin in normal bone and bone metastasis 
(Figure 7).
In normal bone αSMA protein expression was seen 
in arteries/arterioles in the hematopoietic marrow (Figure 
7A). In osteolytic bone metastases arteries were labeled 
and also various scattered stroma cells stained positive 
for αSMA (Figure 7B). In osteoblastic bone metastasis, 
αSMA positive vessels, in proximity to the bone surface, 
are reminiscent of sinusoidal vessels (Figure 7C). In 
osteolytic bone metastasis a trend for more aSMA positive 
staining area was found, however, this was statistically not 
significant (Figure 7D). Normal bone marrow was devoid 
of β3 tubulin immunoreactivitiy (Figure 7E), however, 
in osteolytic bone metastasis elongated scattered β3 
tubulin positive cells were found (Figure 7F). In contrast, 
in osteoblastic bone metastasis, immunoreactivity was 
attributed to cancer cells (Figure 7G). In osteolytic bone 
metastasis, β3 tubulin positive staining area trend to be 
Table 2: Genes of Acta2 (αSMA) dataset (GSE15062) shared with up-regulated genes common to both, PC-3 and 
MDA-MB231 xenografts
category gene symbols
Angiogenesis Angptl2 Cd248 Ecm1 Eln Tnfrsf12a  
Adipocyte 
proliferation Aebp1      
Blood brain 
barrier Mxra8      
Blood 
coagulation Procr      
Bone turn-over Pkdcc Tcta Wisp2    
Cell adhesion Ddr1 Itga3 Itgbl1 Scarf2 Wtip  
Cell mortility Acta2 Actg2 Bcar1 Marcksl1   
Collagen-
related Adamts2 Cthrc1 Loxl3 Pcolce   
ECM Col18a1 Col4a5 Col6a2 Fbln2   
Fibroblasts Nrep Prrx2 S100a4    
Growth factor Efemp2      
Metabolism Cbr2 Ckb     
Neurogenesis Chac1 Crlf1 Dbn1 Ncs1 Nrep Serpinf1
 Thy1 Unc5b     
Niche Gas1      
Regulation of 
growth Gadd45b Wtip     
Smooth 
muscle cell 
proliferation
Csrp2      
Wnt signaling Dact3 Dkk3 Frzb Fzd2 Fzd8 Trabd2b
Others Ahnak2 Akr1b8 Apoe Arhgef5 Ccdc12 Chst14
 Crtap Dbndd2 Ddah2 Eva1b Fhl2 Gpsm1
 Hspb2 Lurap1l Ly6a Meg3 Nnmt Pcbp4
 Pfdn1 Phlda3 Pkp1 Pxdc1 Rabac1 Sod3
 Tagln Tmed1 Tmem109 Tmem184b Trim47 Tubb6
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higher, however, this was statistically not significant 
(Figure 7H).
Our findings indicate the cell types staining positive 
for aSMA and β3 tubulin at different in osteolytic and 
osteoblastic bone metastasis. Our findings suggest 
similarly to the mouse model, that osteolytic bone 
metastasis consist of arteries, whereas osteoblastic 
bone metastasis are characterized by sinusoidal vessel 
structures.
DISCUSSION
This is the first systematic transcriptome analysis 
defining the bone/bone marrow stroma reaction in 
xenograft models of prostate and breast cancer-induced 
osteolytic bone metastasis. The stroma specificity of this 
transcriptome has been achieved by using bioinformatic 
tools discriminating tumor stroma (mouse transcripts) 
from cancer cell (human transcripts) transcriptomes.
Despite their distinct primary tumor origin, 
osteolytic prostate and breast cancer cells induce the 
same phenotypic stroma response in radiography images. 
Consistently, these cancer cells induce similar gene 
expression changes in the bone/bone marrow stroma.
One of the most enriched pathways induced in the 
bone/bone marrow stroma in response to osteolytic cancer 
cells is the axon guidance pathway. Genes within the 
axon guidance pathway have been shown to be involved 
in tumor progression and metastasis [22–24]. It has been 
also shown that in primary prostate and breast tumors 
autonomic nerve development contributes to cancer 
progression [25, 26]. Interestingly, elongated (neurite-like) 
and scattered cells can be found in the stroma of osteolytic 
bone metastasis. These cells express class 3 β tubulin and 
Gap43. Initially, class 3 β tubulin was commonly used as 
a neuron-specific marker, however, as a component of the 
mitotic spindle, its expression can be found in multiple 
cell types, including fibroblasts and cancer cells [27, 28]. 
Gap43 expression is associated with neurite outgrowth 
[29] and interestingly a component of the hematopoietic 
stem cell niche [30]. In osteolytic bone metastasis neurite-
like structures are found intra-tumoral, therefore, Gap43 
positive cells likely re-present an osteolytic cancer cell 
niche component. Previously, nerve growth factor induced 
Gap43 positive nerve fiber sprouting and re-organisation 
has been reported in a mouse breast cancer bone metastasis 
model [31]. Inhibition of nerve growth factor diminished 
the effect and attenuated bone pain.
In normal physiology, the central and peripheral 
nervous system controls bone remodelling [32]. Systemic 
activation of the sympathetic nervous system using a β1/2 
adrenergic receptor non-selective agonist (isoproterenol) 
or chronic stress stimulates bone resorption and 
inhibits bone formation [33]. Isoproterenol stimulates 
Rankl secretion in osteoblasts leading to increased 
osteoclastogenesis and migration of cancer cells. In a 
breast cancer bone metastasis mouse model, betablocker, 
propranolol, prevented bone metastases [33].
Nerve fibers and larger blood vessels, such as 
arteries, align into two parallel structures [34]. Vessel 
patterning occurs in response to nerve-derived signals, 
and vice versa, vascular cell types can produce guidance 
cues for axons. Vascular patterning and growth processes 
are regulated by axon guidance cues [34]. In our RNA 
Figure 7: The stroma of human osteolytic bone metastases consist of arteries. Immunohistochemical detection of αSMA 
(A-C) and β3 tubulin (E-G) in normal bone (A, E), in osteolytic bone metastasis (B, F) and in osteoblastic bone metastasis (C, G). Scale 
bar = 50 μm. Positive staining area of αSMA (D) and β3 tubulin (H) was quantified in 2 specimens of osteoblastic bone metastasis and 3 
specimens of osteolytic bone metastasis. Dotted line in panel C highlights the bone surface.
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sequencing data, we found some axon guidance genes 
specifically up-regulated in the stroma of osteolytic bone 
metastasis suggesting that osteolytic cancer cells use axon 
guidance cues to generate an arterial network in the bone/
bone marrow stroma.
Members of the semaphorin family are also part of 
the axon guidance pathway. Besides an involvement in 
neurite growth, these axon guidance molecules have also 
various other functions. Under physiological conditions, 
Semaphorin 3B and 7A are known to stimulate osteolysis 
and fusion of osteoclast progenitors, respectively [35, 36]. 
The observation that osteolytic cancer cells also induce 
expression of semaphorin family members in the bone/
bone marrow compartment is novel and might be an 
additional mechanism to stimulate bone resorption. The 
function of most induced semaphorin family members on 
osteoclasts is not yet investigated, it would be worthwhile 
to study their functions in future experiments.
Osteolytic lesions are also the result of a decrease 
in osteoblast-mediated bone formation [7]. Previously, it 
was reported that osteolytic cancer cell growth is inhibited 
by the presence of osteoblasts [37]. Our data indicate that 
osteolytic breast and prostate cancer cells in vivo instruct 
the stroma to express Bmp/Wnt antagonists, which further 
suppress bone formation.
Another enriched process in the stroma of bone 
metastasis is angiogenesis. Angiogenesis is tightly 
coupled to osteoclastogenesis and bone formation in 
physiology and pathophysiology [38, 39], therefore, 
it was not entirely surprising that angiogenesis is an 
enriched pathway in both, osteolytic and osteoblastic 
bone metastasis. However, the vasculature was markedly 
different in osteolytic and osteoblastic bone metastasis. 
The sinusoidal morphology in osteoblastic metastasis 
resembles the physiological bone marrow vasculature, 
whereas in osteolytic bone metastasis the tumor 
vasculature was remodelled. Osteolytic cancer cells 
induce an arterial network in the stroma. Interestingly, in 
normal bone physiology, an arterial network is associated 
with hematopoietic stem cell (HSC) quiescence [40]. Our 
data shows that osteolytic cancer cells induce an arterial 
network, which might create a cancer cell niche beneficial 
to support cancer cell growth. The dormancy niche of 
HSC consist also of non-myelinating Schwann cells [41]. 
Schwann cells express various markers, among them 
Ng2 [42], and process latent TGF-β into active TGF-β in 
the bone marrow. Interestingly, we found Ng2 positive 
cells in osteolytic bone metastasis. These Ng2 positive 
cells could be Schwann cells providing active TGF-β to 
support cancer cell growth. Schwann cells also direct 
neurite outgrowth, and these might be the cells directing 
neurite ingrowth seen in osteolytic bone metastasis [43]. 
One key molecule in physiological artery specification is 
Sonic hedgehog (Shh), which stimulates Notch signaling 
and thereby inducing the arterial program [44]. In future 
it would be interesting to study the effects on osteolytic 
cancer growth upon disruption of the arterial network.
The predominant accumulation of smooth muscle 
cells/cancer-associated fibroblasts was interesting and 
evident only in osteolytic bone metastasis. The origin of 
these cells remains unclear. We have proven that these 
cells are of stromal origin and not cancer cells with a 
mesenchymal phenotype. Previously, it has been reported 
that in fibrosis fibroblasts can originate from endothelial 
cells [45]. Therefore, it is tempting to speculate that in the 
context of bone metastasis, cancer-associated fibroblasts 
are also derived from endothelial cells undergoing a 
mesenchymal transition. Interestingly, the upstream 
activator of the osteolytic stroma response with the highest 
activation score is Tgfβ, a potent inducer of endothelial to 
mesenchymal transition [45]. The growth support provided 
by mesenchymal cells to cancer cells beyond osteolytic 
cytokines and the expression of BMP/Wnt antagonists 
remains unclear. The overlap with an expression profile 
of αSMA positive cells yielded a list of interesting target 
genes that could be investigated as targets to interfere with 
osteolytic cancer cell growth at the bone/bone marrow site. 
Our study is in line with a previous study reporting that a 
cancer-associated fibroblast signature is overrepresented 
in bone metastases, as compared to lung, liver and brain 
metastases [46]. We observed cancer-associated fibroblasts 
(αSMA positive cells) in samples of human osteolytic 
bone metastasis. Fibroblast-like cells were previously 
described to mediate osteoclast-independent resorption, 
which could explain why these cells are present in 
osteolytic bone metastasis [47]. In human osteolytic bone 
metastasis cancer-associated fibroblasts and arteries are 
αSMA positive. Arteries were exclusively observed in 
osteolytic bone metastasis, whereas in osteoblastic bone 
metastasis vessels displayed a sinusoidal morphology.
Taken together, this study provides a systematic 
analysis of upstream regulators and altered pathways 
associated with the stroma response in osteolytic bone 
metastasis.
MATERIALS AND METHODS
Ethics statement
The Committee for Animal Experimentation 
and the Veterinary Authorities of the Canton of Bern, 
Switzerland approved the experimental animal protocols, 
anesthesia, surgical procedures and post-surgical analgesia 
(Permit Number: 15/07 and 6/10). Mice were housed in 
individual ventilated cages in strict accordance to the 
Swiss Guidelines for the Care and Use of Laboratory 
Animals. Autoclaved water and sterile mouse chow were 
provided ad libitum. For surgical manipulation, mice 
were anesthetized with a cocktail of medetomidin (1 mg/
kg body weight), midazolam (10 mg/kg) and fentanyl 
(0.1 mg/kg). Post-operative analgesia with buprenorphine 
(0.1 mg/kg) was performed for 3 days following surgical 
intervention. Animals xenografted with human cancer cells 
Oncotarget28891www.oncotarget.com
were monitored for signs of pain, distress and loss of body 
weight. Development of bone lesions was followed by 
radiography at weekly intervals for PC-3, MDA-MB231, 
VCaP and 4T1.2 cells. At the experimental endpoint mice 
were sacrificed by CO2 euthanasia.
The Ethical Committee of the Canton of Bern, 
Switzerland, approved the overall study protocol and 
tissue collection from patients (Nr 06/03). A written 
informed consent was obtained from each patient.
Cell culture
The osteolytic prostate cancer cell line PC-3 (ATCC 
CRL1435) was grown in DMEM and the prostate epithelial 
cell line Ep156T (kindly donated by V. Rotter, Department 
of Molecular Cell Biology, Weizmann Institute of Science, 
Rehovot, Israel) in modified MCDB-153 medium (WKS 
Diagnostics, Frankfurt am Main, Germany) supplemented 
with 5 ng/ml epidermal growth factor (Invitrogen), 10 nM 
R1881 and 50 ug/ml bovine pituitary extract (Gibco). The 
breast cancer cell line MDA-MB231 (ATCC-HTB-26) 
was grown in RPMI 1640 (Biochrom AG, Berlin, 
Germany) supplemented with sodium pyruvate. The 
mouse breast cancer cell line 4T1.2 (kindly donated by 
CR. Anderson, University of Melbourne, Melbourne) was 
grown in RPMI 1640 (Biochrom AG, Berlin, Germany). 
The human osteoinductive prostate cancer cell line VCaP 
(kindly donated by K. Pienta, University of Michigan, Ann 
Arbor) was grown in RPMI 1640 medium (Biochrom AG, 
Berlin, Germany).
All media were supplemented with 10% heat-
inactivated fetal bovine serum gold (PAA, The Cell 
Culture Company).
Titration of osteolytic cancer cells
A major difficulty in working with xenografts 
of osteolytic cancer cells is the rapidity by which bone 
lesions develop. The bone marrow ablation procedure, 
necessary to create space for implanting cancer cells in 
the marrow cavity, induces a wave of bone formation. The 
wave of bone formation normalizes within 2 weeks [48, 
49]. It was necessary to determine the minimal inoculum 
of PC-3 cells able to generate an osteolytic reaction while 
allowing a sufficient lag-phase for the animals to recover 
to ensure that the stroma gene expression profile induced 
by the osteolytic cancer cells would not be influenced 
by the response due to marrow ablation. Constitutively 
firefly luciferase-expressing PC-3 cells were used to 
determine the onset of osteolytic lesions using different 
cell numbers. Single-cell suspensions of 2.500 (n=2), 
5.000 (n=2), 10.000 (n=2), 20.000 (n=2), 50.000 (n=2) 
cells per 10ul phosphate-buffered saline (PBS) or 10ul 
PBS (n=2)(sham) were injected into the bone marrow 
cavity of the left tibia of mice. Intra-osseous tumor growth 
was monitored non-invasively in the living animals by 
bioluminescent imaging (BLI) at weekly intervals as 
previously described [50] using an ultrasensitive charge-
coupled device (CCD) camera (NightOWL LB, Berthold 
Technologies, Bad Wilbad, Germany). The inoculation of 
decreasing numbers of cancer cells resulted in a delayed 
tumor onset but did not modify growth rate and tumor 
take. Based on these results, the in vivo experiment for 
RNA sequencing was performed using 2500 PC-3 cells 
(shown in Supplementary File).
Bone metastasis mouse models
For intra-osseous xenografts, human prostate (PC-
3 cell line) and breast (MDA-MB231 cell line) cancer 
cells with the capacity to induce an osteoclast reaction 
(osteolytic cancer cells) and human prostate cancer cells 
with capacity to induce an osteoblastic response (VCaP 
cell line) and immortalized, non-tumorigenic human 
prostate epithelial Ep156T cells were inoculated in the 
bone marrow cavity of the left tibia of male CB17 SCID 
mice as previously described [51]. Sham-operated animals 
(sham) and animals not subjected to surgery (intact) 
were used as controls. Development of bone lesions 
was monitored by radiography (MX-20, Faxitron X-Ray 
Cooperation, Edimex, Le Plessis, France). PC-3 and 
MDA-MB231 xenografts and Ep156T control animals 
were sacrificed after 33 days. Mice xenografted with 
VCaP and sham-operated were sacrificed after 72 days. 
Sham and intact animals were sacrificed at day 33 for 
PC-3 and MDA-MB231 xenografts and at day 72 for 
VCaP xenografts. Xenografted and control tibiae were 
used either for RNA isolation, immunohistochemistry, 
immunofluorescence or FACS.
As a systemic bone metastasis model, human 
osteolytic breast cancer cells (MDA-A12luc cells) were 
injected into the left cardiac ventricle and tumor growth 
was monitored using bioluminescent imaging (NightOWL 
LB, Berthold Technologies, Bad Wilbad, Germany) and 
radiography (MX-20, Faxitron X-Ray Cooperation, 
Edimex, Le Plessis, France). As a syngeneic bone 
metastasis model, mouse osteolytic breast cancer cells 
(4T1.2 cells) were intra-osseously injected in Balb/c mice. 
Sham-operated animals were used as controls.
RNA extraction
Total RNA was isolated using TRIzol (Invitrogen) 
according to the manufacturer’s instructions. RNA 
was quantified using the NanoDrop spectrophotometer 
(NanoDrop Technologies, Wilmington, Delaware, USA). 
The RNA quality was determined using RNA 6000 Nano 
Kit (Agilent Technologies), all RNA samples had a RNA 
integrity number (RIN score) more than 7. Total RNA 
without any further DNase treatment was used for RNA 
sequencing. The ratio of human to mouse RNA in the 
xenograft samples was determined by measuring 18S and 
Oncotarget28892www.oncotarget.com
both mouse and human β2-microglobulin, hypoxanthine 
phosphoribosyltransferase 1 and actin beta expression 
with RT-qPCR. For subsequent cDNA synthesis Trizol 
extracted RNA was cleaned up using a RNeasy Mini 
cleanup kit (Qiagen). The protocol also consisted of a 
DNase digestion step (Kit from Qiagen).
For FACS experiments, cells were directly sorted 
into lysis buffer. RNA was isolated using a RNA mini kit 
(Qiagen). Subsequently, RNA samples were amplified 
using a REPLI-g Single Cell RNA Library Kit.
For laser-captured micro-dissection analysis, RNA 
was isolated from specimens using a RNA mini kit 
(Qiagen).
RNA sequencing and data analysis
For the identification of differentially expressed 
genes between the physiological bone/bone marrow 
stroma and that in established osteolytic bone metastasis, 
samples from 13 mice were analyzed. Tibiae from mice 
xenografted with osteolytic prostate (PC-3 cells (n=3)) 
and breast (MDA-MB231 cells (n=4)) cancer cells were 
analyzed. As controls, we analyzed tibiae xenografted 
with prostate epithelial non-tumorigenic cells (Ep156T)
(n=3) and tibiae from control mice (intact tibiae with no 
intervention) (n=3). Previously, we have shown that all 
control samples - namely, intact bones, sham-operated 
bones and Ep156T xenografted bones - show a similar 
gene expression profile based on hierarchical clustering 
of our microarray data [19]. Only a single gene, namely 
MMP12, was differentially expressed between intact 
bones and sham-operated/Ep156T-xenografted bones. 
Therefore, in this study we included as controls intact 
bones and Ep156T xenografted bones.
As the stromal response could be tumor size-
dependent, we selected RNA samples derived from a group 
of mice with tumors of comparable size for each group 
(PC3 and MDA-MB231 xenografts). We determined the 
percentage of human and mouse RNA by real-time PCR 
using species-specific primers of housekeeping genes. 
This measurement estimates the percentage of tumor 
(human transcripts) versus stroma (mouse transcripts). 
The selected samples for RNA sequencing had an average 
of 93% mouse transcripts (stroma) in PC-3 xenografts 
and 73% mouse transcripts (stroma) in MDA-MB231 
xenografts (Supplementary File). RNA samples of (a) 
tibiae xenografted with PC-3 and MDA-MB231 cells, 
(b) intact bones and (c) tibiae xenografted with human 
non-tumorigenic prostate epithelial cells (Ep156T) were 
subsequently sequenced using an Illumina platform. 
First, we analyzed whether all reads can be unequivocally 
assigned to either human or mouse transcripts. In total, 
reads from 245 genes could not be unequivocally 
assigned to either human or mouse (Supplementary 
Table 4) and were therefore excluded from subsequent 
analyses. Furthermore, we analyzed whether genes were 
differentially expressed between Ep156T xenografted 
bones and intact bones. In total, 73 genes were 
differentially expressed, among which 68 genes were up-
regulated and 5 genes were down-regulated (fold change > 
±2, adjusted p value < 0.01) (Supplementary Table 5). The 
latter result indicated that the surgical manipulation with 
inoculation of human epithelial cells did not considerably 
alter the stroma gene expression.
PC-3 xenografts
Paired-end high-throughput RNA sequencing of 
PC-3 xenografts, Ep156T xenografts and intact samples 
was performed on the Illumina/Solexa GAII platform 
(Illumina Inc, San Diego, CA, USA) by the ServiceXS 
Sequencing Facility (Leiden, Netherlands).
The Illumina mRNA sequencing sample preparation 
kit was used to process all RNA samples. In brief, after 
isolation of mRNA from total RNA using poly-T-oligo-
attached magnetic beads, mRNA was fragmented 
(using divalent cations), which yielded an average 
size of 200 nucleotides (fragment library). Following 
cDNA synthesis, cDNA was ligated with adapters and 
amplified by PCR. The quality and yield was evaluated 
using a DNA 1000 kit (Agilent Technologies). cDNA 
fragments were hybridized onto an Illumina glass flow 
cell, fragments were amplified into a cluster using bridge 
amplification. 8pmol of DNA per sample was sequenced. 
Two sequencing reads of 75 cycles each using the Read 
1 sequencing and Read 2 sequencing primers were 
performed using a glass flow cell. Sequencing files were 
generated in FastQ format.
Pre-processing
Image analysis, base calling, and quality check 
was performed with the Illumina Genome Analyzer data 
analysis pipeline RTA v1.8.80.0 and/or OLB v1.8 and 
CASACA v1.7.0.
FastQ files were filtered by removing reads with 
more than 20% of nucleotides having Phred quality scores 
less than 20 (probability of incorrect base call 1%).
Alignment of human reads to reference genome
Reads were mapped to the human genome hg19 
(GCA_000001405.1) using the Bowtie aligner version 
0.12.7 (http://bowtie.cbcb.umd.edu/).
Alignment of mouse reads to reference genome
Sequenced fragments that did not map to the 
human reference genome were paired by matching 
forward and reverse reads based on their IDs and then 
aligned to the Mus musculus reference genome (Mus_
musculus.NCBIM37.60.dn) using TopHat version 1.4.0. 
Per gene (ftp://ftp.ensembl.org/pub/release-60/gtf/mus_
musculus/) the amount of aligned reads was counted 
(https://htseq.readthedocs.io/en/release_0.9.1/history.
html#version-0-4-5) and stored in count files.
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MDA-MB231 xenografts
The paired-end RNA sequencing was performed 
using an Illumina HiSeq 2000 sequencer. The paired-
end mRNA-Seq reads were filtered using a Q22 Phred 
score as a minimum. Bases with Phred scores below this 
score were removed, only reads longer than 36 bases 
were retained. The reads were aligned to a combined 
transcriptome reference derived from draft versions mm9 
as mouse reference and hg19 as human reference. This 
combined reference approach separates the dataset by 
mapping paired-end reads to genes of a specific organism 
using the aligner (BWA version 0.5.9). The approach used 
data from both human and mouse reads from the sequence 
read archieve (SRA), resulting in a mapping mismatch rate 
of 0.005% and 0.8% respectively.
Tophat version 1.4.0 and Bowtie version 0.12.7 
align the separated reads to the mm9 (Mus_musculus.
NCBIM37.60.dn) and hg19 (GCA_000001405.1) genome 
references. Per gene (ftp://ftp.ensembl.org/pub/release-60/
gtf/mus_musculus/) the amount of aligned reads was 
counted (https://htseq.readthedocs.io/en/release_0.9.1/
history.html#version-0-4-5) and stored in count files.
In PC-3 xenografts 2141 genes are differentially 
expressed compared to control bones, as opposed to 
6476 differentially expressed genes in MDA-MB231 
xenografts. This higher number of differentially expressed 
genes could be due to different sequencing depth. The 
different sequencing depths for PC-3 and MDA-MD231 
samples occur due to different sequencing technology. In 
PC-3 samples (n=3) 6'730'384, 9'524'486 and 9'503'449 
total reads overlapped with annotated genes, whereas in 
MDA-MB231 samples (n=4) 26'422'805, 12'982'791, 
20'323'365 and 20'897'481 total reads overlapped with 
annotated genes. Furthermore, the statistical power 
to detect differentially expressed genes in MDA-
MB231 xenografts compared to controls is higher due 
to 4 replicates as compared to three replicates for PC-3 
xenografts and therefore, it is also likely that more 
differentially expressed genes are identified. Finally, 
MDA-MB231 tumors were more advanced (based on 
the measurement of the human to mouse ratio) when we 
isolated the RNA for sequencing. This could also explain 
why more stromal genes are differentially expressed as 
compared to PC-3 xenografts.
Quantification of gene expression and 
identification of differentially expressed genes 
(DESeq2)
Differential gene expression was calculated from 
raw read counts using Deseq2 v. 1.6.1. (adjusted pvalue 
of <0.01). Gene expression differences were measured 
using log2 fold change. A gene was considered to be 
differentially expressed if it had a Benjamini-Hochberg 
adjusted P-value < 0.01.
Principal component analysis (PCA) plot
The first two axes from a PCA plot in DESeq2 v. 
1.6.1. were plotted to visualize the similarity of gene 
expression profiles among samples. A regularized log 
transformation was applied to the counts before PCA.
Reverse transcription quantitative PCR (RT-
qPCR)
First strand cDNA was synthesized using 2 ug of 
total RNA, 8U/μl MMLV Reverse Transcriptase, 10 ng/
μl random primer, 0.4mM dNTPs and 1.6U/μl RNase 
inhibitor (all Promega, Wallisellen, Switzerland).
For laser-captured microdissection samples, 
cDNA was synthesized using SuperScript™ II Reverse 
Transcriptase (ThermoFisher Scientific).
mRNA expression was measured by real-time-
qPCR using species-specific TaqMan gene expression 
assays. The mouse and human specific gene expression 
assays are listed in Supplementary Table 6. ABI-Prism 
7500 Sequence Detection System (Applied Biosystems, 
Rotkreuz, Switzerland) was used to analyze the samples. 
Gene expression was either normalized to a panel 
of housekeeping genes (ACTB, B2M, HRPT1, 18S) 
to dermine the mouse versus human ratio or to β-2-
microglobulin to validate differentially expressed target 
genes. RNA expression data were analyzed with two-
tailed, unpaired t-test using GraphPad Prism version 6.0 
(GraphPad Software Inc., La Jolla, USA).
Immunohistochemistry and immunofluorescence
Immunohistochemical staining was performed on 
deparaffinized tissue sections with the primary antibodies 
listed in Supplementary Table 7. Antibodies were 
detected using horseradish peroxidase-conjugated biotin-
streptavidin (GE Healthcare, Glattbrugg, Switzerland) or 
EnVision (Dako, Baar, Switzerland) systems. 3-Amino-9-
ethyl-carbazole (AEC, Sigma) was used as a chromogen. 
Sections were counterstained with hematoxilin.
Immunofluorescence staining was performed on 
undecalcified tissue sections [52] with the primary and 
secondary antibodies listed in Supplementary Table 7. 
Sections were counter-stained with Dapi.
Samples of normal bone were obtained from patients 
with coxarthrosis. Prostate cancer bone metastasis samples 
were derived from iliac crest and femur, while breast 
cancer bone metastasis samples were from the humerus.
Quantification of stainings were performed using 
ImageJ.
Labeling of arteries in vivo
Alexa Fluor 633 hydrazide (Invitrogen) was intra-
venously injected in mice 5 minutes before euthanasia 
Oncotarget28894www.oncotarget.com
to label arteries [20]. Undecalcified frozen bone sections 
were prepared from Alexa Fluor 633 injected animals.
FACS
We analyzed intact tibiae (n=5), sham-operated 
tibiae (n=5) and MDA-MB231 xenografted tibiae (n=5) 
to determine the number of MSCs. Tibiae were crushed 
and digested for 15min at 37 degrees at 110 revolutions 
per minute. The digestion solution was prepared in 
1xPBS/0.5% BSA containing 1.25 mg/ml Collagenase II 
(Worthington), 1.25 mg/ml Collagenase IV (Sigma C5138) 
and 0.25 mg/ml deoxyribonuclease (Roche, 11284932001). 
To deplete hematopoietic cells, the cell suspensions were 
stained with Cd45- and Ter119-biotinylated antibodies 
and subsequently stained with anti-biotin beads to deplete 
Cd45 and Ter119 positive cells using MACS separation 
columns (130-042-401). Remaining cells were stained for 
Cd31, Sca1, Cd51, Cd140a and HLA-A2 (labels human 
cells). Cells were then analyzed using FACS Aria. MSCs 
were characterized by the following marker expression: 
Cd45-, Ter119-, Cd31- and Sca-1+, Cd51+, Cd140a+.
For the RNA expression analysis, we pooled MSCs 
sorted from either sham-operated tibiae or MDA-MB231 
xenografted tibiae. Alpha SMA positive cells from intact 
(n=3) and MDA-MB231 xenografted (n=3) tibiae were 
sorted after depletion of hematopoietic cells. We pooled 
αSMA positive cells from either intact or MDA-MB231 
xenografted tibiae and then analyzed the expression profile.
Identification of key biological processes, 
pathways, up-stream regulators
Differentially expressed genes were analyzed for 
enriched gene ontology (GO) terms, enriched KEGG 
pathways (DAVID 6.7) and to create a functional protein 
network (STRING, 9.05; confidence score = 0.4). The 
upstream regulators were predicted by using Ingenuity 
Pathway Analysis software.
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